logo-loader

Summit Therapeutics says new data on selective antibiotic shows potency for treatment of clostridium difficile infection

Published: 13:39 05 Jun 2017 BST

Test tubes
He added: “We believe ridinilazole has the potential to be a novel, and urgently needed, front-line treatment option for this serious disease"

Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT) saw its shares jump 4% after the drug developer said new preclinical data on ridinilazole, a novel and selective antibiotic for the treatment of clostridium difficile infection (CDI), had been presented at ASM Microbe 2017 in New Orleans.

The AIM and Nasdaq-listed firm said the results, presented in two poster presentations at the US conference over the first five days of June, showed that ridinilazole was very active against all CDI isolates with overall minimum inhibition concentrations distributed over a very narrow range.

READ: Summit Therapeutics strengthens R&D team

David Roblin, Summit’s president of research & development, said: "These positive preclinical data presented at ASM Microbe highlight the potency of ridinilazole against a wide range of CDI clinical isolates from patients with CDI.”

He added: "Combining potency and selectivity, ridinilazole has shown positive results in clinical trials that support its potential to treat patients with CDI and reduce the rate of recurrent disease.

“It is thought that the preservation and restoration of the patient microbiome is important in reducing recurrence and ridinilazole's narrow spectrum is designed to achieve this.

“We believe ridinilazole has the potential to be a novel, and urgently needed, front-line treatment option for this serious disease.”

In early afternoon trading Summit shares were 4.1%, or 7.5p higher at 182.5p.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

50 minutes ago